OncoSec Medical to Present at Five Events in September

OncoSec Medical Inc. (OTCQB:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at five events in September. The company’s agenda includes a number of high-profile scientific and investment conferences.

Rodman and Renshaw 16th Annual Global Investment Conference

Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual Rodman & Renshaw Global Investment Conference, taking place at the New York Palace Hotel in New York City, NY September 8-10, 2014. The presentation will be held on Tuesday, September 9th in the Kennedy 1 Salon (4th floor) at 10:25 AM ET.

At the time of the presentation, a live webcast will be available via the following link: http://wsw.com/webcast/rrshq24/oncs

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available in the “Events” section of the OncoSec web page at http://www.oncosec.com

Rodman & Renshaw 2014 Annual Global Investment Conference will attract over 250 public and private companies from around the world to present to an audience of over 2,000 engaged attendees. The event will feature corporate presentations, Q&A sessions, 1-on-1 meetings and daily networking opportunities meant to facilitate discussions between institutional investors, venture capitalists, private equity firms, sophisticated private investors and leading industry executives. For more information, please visit http://www.rodm.com

Aegis Capital 2014 Healthcare and Technology Conference

Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2014 Aegis Capital Healthcare and Technology Conference, taking place September 10-13 at The Encore at Wynn in Las Vegas, Nevada. The presentation will be held on Thursday, September 11th in Room 2 at 9:45 AM PT.

The 2014 Healthcare and Technology Conference will showcase more than 90 emerging and established companies in the healthcare and technology sectors. The event will feature company presentations, networking receptions and 1-on-1 investor meetings. For more information, please visit http://www.aegiscapcorp.com

TEDx KPU

Tu Diep, Executive Director, Clinical Development, will present a discussion titled, “The Miseducation of the Immune System“, at TEDx KPU on September 27, 2014. The event will be hosted at Kwantlen Polytechnic University (KPU) in Richmond, BC, Canada.

TEDx KPU will engage students, employees and the KPU community in a day of discussion, education and narratives from a variety of inspiring speakers aligned with the event’s theme, “Moment of Genius”. These activities are designed to create an event that will live up to the reputation of TED. The event will feature speakers that reflect the dynamic and polytechnic characteristics of both KPU and the Greater Vancouver area. For more information, please visit http://www.ted.com/tedx/events/12634

Interface 2014 Digital Health Summit

Punit Dhillon, President and CEO, will attend and present at the Interface 2014 Digital Health International Summit, taking place September 29-30 at the Vancouver Convention Centre in Vancouver, BC, Canada.

Interface 2014 Digital Health Summit is a two-day event designed to engage, inform, inspire and connect digital health innovators and other key stakeholders. This year’s summit will bring together world-leading experts, innovators, disruptors and creative thinkers to discuss the future of health. The event will include interactive exhibits and forums, speaker presentations, educational seminars, and networking activities meant to facilitate partnering and collaboration. For more information, please visit http://interfacesummit.com

Sachs 14th Annual Biotech in Europe Forum: For Global Partnering & Investment

Robert Pierce, M.D., Chief Medical Officer, will present a corporate overview of the company and participate in a panel discussion titled, “Building the Cancer Focused Biotech”, at the 14th Annual Sachs Biotech in Europe Forum, taking place September 30th to October 1st at Congress Center Basel in Basel, Switzerland. The panel discussion will begin at 12 PM CET on Tuesday, September 30th. The presentation will begin at 4:30 PM CET on Tuesday, September 30th in the Darwin room.

At the time of the presentation, a live webcast will be available via the events section of the OncoSec web page at http://www.oncosec.com. OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available on the website.

The Sachs Annual Biotech in Europe Forum is recognized as a leading international stage for investing and partnering in the biotech and life science industry. This year’s event will bring together more than 100 presenting companies and over 600 delegates to interact with leading investors, analysts, money managers and pharma licensing executives in a highly transactional environment. The forum will feature plenary panels, workshops, presentations, and 1-on-1 meetings meant to facilitate networking and discussion among attendees and participants. For more information, please visit http://www.sachsforum.com/basel14/index.html

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:OncoSec Medical Inc.Veronica Vallejo, 855-662-6732CFOinvestors@oncosec.com

OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024